Celldex Therapeutics (CLDX) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Celldex (CLDX) Bullish Stance Reiterated at Cantor Fitzgerald Following Q1 and Update
April 30, 2015 9:42 AM EDTCantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating and $38 price target on Celldex Therapeutics (NASDAQ: CLDX) following in-line Q1 results and an pipeline update.
The analyst notes that at the end of the quarter, Celldex had $360 million in cash. "This seems sufficient to us to last into 2017, though could be impacted by the regulatory and commercialization plans for Rintega (rindopepimut),"... More
